A relatively low-tech stock trade is making Tesla Inc.’s dizzying rally look like an under-performance.
A New York state lawsuit is renewing longstanding questions about where some members of the billionaire Sackler family have invested the wealth they amassed from Purdue Pharma LP, the drugmaker accused of helping ignite the U.S. opioid epidemic.
Makers of medical device implants and diagnostic products proved health care was no monolith after broadly outperforming the U.S. market and their health care brethren in 2018. But 2019 is shaping up quite differently through the first day of trading amid a spotlight from a variety of investment banks.
Increasing wariness in Washington over China’s investments in U.S. biotechnology companies may cool a hot source of capital for medical startups.
As Biogen Inc. prepares to kick off earnings season Tuesday for a beaten-down large-cap biotechnology sector, investors won’t be too focused on the financial results.